Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0026 | 0.6476 | 1 |
Plasmodium falciparum | acyl-CoA synthetase | 0.002 | 0.4158 | 0.9078 |
Brugia malayi | AMP-binding enzyme family protein | 0.0026 | 0.6476 | 0.6476 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.4581 | 1 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0026 | 0.6476 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0021 | 0.4581 | 0.7073 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.4581 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0021 | 0.4581 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.4158 | 0.6421 |
Toxoplasma gondii | exonuclease III APE | 0.0021 | 0.4581 | 1 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0021 | 0.4581 | 0.7073 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.4581 | 0.4581 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD3 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0019 | 0.3784 | 0.5844 |
Brugia malayi | AMP-binding enzyme family protein | 0.0026 | 0.6476 | 0.6476 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.4581 | 1 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0021 | 0.4581 | 0.5 |
Onchocerca volvulus | 0.0026 | 0.6476 | 1 | |
Mycobacterium ulcerans | hypothetical protein | 0.0026 | 0.6476 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.0026 | 0.6476 | 0.6476 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0026 | 0.6476 | 1 |
Chlamydia trachomatis | acylglycerophosphoethanolamine acyltransferase | 0.002 | 0.4158 | 0.5 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD35 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0019 | 0.3784 | 0.5844 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0021 | 0.4581 | 0.4581 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.4158 | 0.6421 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0026 | 0.6476 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0026 | 0.6476 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0026 | 0.6476 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0021 | 0.4581 | 0.7073 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD7 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0019 | 0.3784 | 0.5844 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.4158 | 0.6421 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0021 | 0.4581 | 1 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD5 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0019 | 0.3784 | 0.5844 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0021 | 0.4581 | 1 |
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.4158 | 0.6421 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0021 | 0.4581 | 0.4581 |
Entamoeba histolytica | acyl-coA synthetase, putative | 0.0026 | 0.6476 | 0.6476 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0021 | 0.4581 | 0.4581 |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0026 | 0.6476 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0021 | 0.4581 | 0.7073 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0026 | 0.6476 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0026 | 0.6476 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0021 | 0.4581 | 0.4581 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.002 | 0.4158 | 0.6421 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0021 | 0.4581 | 1 |
Mycobacterium tuberculosis | Fatty-acid-AMP ligase FadD30 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) | 0.002 | 0.4158 | 0.6421 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.6476 | 1 |
Plasmodium vivax | acyl-CoA synthetase, putative | 0.002 | 0.4158 | 0.9078 |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0026 | 0.6476 | 0.6476 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0021 | 0.4581 | 0.5 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.6476 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0021 | 0.4581 | 0.4581 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0021 | 0.4581 | 1 |
Leishmania major | 4-coumarate:coa ligase-like protein | 0.0026 | 0.6476 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.002 | 0.4158 | 0.6421 |
Entamoeba histolytica | acyl-CoA synthetase, putative | 0.0026 | 0.6476 | 0.6476 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 26 nM | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hrs by fluorescence based method | ChEMBL. | 20088608 |
IC50 (functional) | = 27 nM | Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 72 hrs by fluorescence based method | ChEMBL. | 20088608 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 20088608 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.